IndraLab
Statements
Ecgonine benzoate inhibits MYD88. 2 / 2
|
2
reach
"Although the therapeutic mechanism of BCG is still unclear, available evidence suggests that innate and adaptive immunity play key roles in BCG treatment, which produces pathogen-associated molecular patterns that can be recognized by host pattern recognition receptors (e.g., TLR2, TLR4, and TLR9, etc.), which induces MyD88 signaling to regulate pro-inflammatory cytokine production, and MyD88 deficiency leads to reduced response to BCG treatment in mice (114)."